Regulating Formularies: OIG Wants Closer Scrutiny of Process; CMS Says Focus on Results
This article was originally published in RPM Report
The HHS Inspector General is concerned about lax oversight of conflict-of-interest standards on formulary committees for Medicare Part D plans. CMS is defending its approach, which emphasizes review of the formularies themselves, rather than the process to construct them. For biopharma companies, the “right” regulatory model for formulary oversight is an important issue as health care reform evolves.